Seize the opportunity: underutilization of fine-needle aspiration biopsy to inform targeted cancer therapy decisions.
about
Analysis of Pre-Analytic Factors Affecting the Success of Clinical Next-Generation Sequencing of Solid Organ MalignanciesFunctional profiling of live melanoma samples using a novel automated platformMolecular testing guidelines for lung adenocarcinoma: Utility of cell blocks and concordance between fine-needle aspiration cytology and histology samples.EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection.Comparative study of epidermal growth factor receptor mutation analysis on cytology smears and surgical pathology specimens from primary and metastatic lung carcinomas.EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients.Microfluidic device for mechanical dissociation of cancer cell aggregates into single cellsAdvances in fine needle aspiration cytology for the diagnosis of pulmonary carcinoma.Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens.Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: a retrospective review of 50 cases.Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review.EGFR analysis: current evidence and future directions.Challenges and opportunities of next-generation sequencing: a cytopathologist's perspective.Comparing endobronchial ultrasound-guided fine needle aspiration specimens with and without rapid on-site evaluation.Two decades of lung cancer through the pages of Cancer Cytopathology.Cytomorphological features as predictors of epidermal growth factor receptor mutation status in lung adenocarcinoma.
P2860
Q26783605-0F4BAD2E-6A95-46BD-8A53-3BE80AAA3E07Q28484649-1035E008-9834-453D-9431-D11728652429Q33760283-22DCF96E-B3EF-49F7-8245-63DC41B1D193Q34096414-118168CC-CF07-48D1-81F5-1638DC866020Q34567984-6C5BB0F0-4DCB-4D45-8BD8-33F4032382BCQ34777840-2DCB9079-EF05-4809-AD66-8ACD3ACB14C0Q34994195-7814C4BC-0A19-4EB9-804E-065099A5AF73Q35110001-26D47B26-764D-4328-ACEC-3BA9FA7EF319Q36364110-540B5D33-9DE3-4EC6-AFBF-78FF19BF450CQ37890996-21B81B9B-8427-4B85-9E98-538512D85547Q37916396-AE4AAE96-8708-4D1C-BD8A-D9EE6244FD68Q38195265-4B9F3C8C-59C3-441A-BBA7-CBF9BF70A45CQ38591866-FF46ADA5-CFC7-406B-83F5-231D0450E390Q41139621-149A3E4A-C8EF-4DC8-B353-B4FB84E5B109Q53082169-ACF03ABB-596B-4158-8AC6-8A2CF8DDBF92Q54979892-112FE09B-C6B4-400E-822F-7168D83EFD91
P2860
Seize the opportunity: underutilization of fine-needle aspiration biopsy to inform targeted cancer therapy decisions.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Seize the opportunity: underut ...... eted cancer therapy decisions.
@en
Seize the opportunity: underut ...... eted cancer therapy decisions.
@nl
type
label
Seize the opportunity: underut ...... eted cancer therapy decisions.
@en
Seize the opportunity: underut ...... eted cancer therapy decisions.
@nl
prefLabel
Seize the opportunity: underut ...... eted cancer therapy decisions.
@en
Seize the opportunity: underut ...... eted cancer therapy decisions.
@nl
P2860
P356
P1433
P1476
Seize the opportunity: underut ...... eted cancer therapy decisions.
@en
P2093
Douglas P Clark
P2860
P304
P356
10.1002/CNCY.20045
P407
P577
2009-10-01T00:00:00Z